🇺🇸 FDA
Patent

US 11993573

Chromane-substituted, tetrahydroquinoline-substituted and thiochromane-substituted heteroarotinoids as anti-cancer agents

granted A61KA61K31/352A61K31/382

Quick answer

US patent 11993573 (Chromane-substituted, tetrahydroquinoline-substituted and thiochromane-substituted heteroarotinoids as anti-cancer agents) held by The Board of Regents for Oklahoma State University expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents for Oklahoma State University
Grant date
Tue May 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K31/352, A61K31/382, A61K31/47, A61P